These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3095121)

  • 21. Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.
    Cervellino JC; Araujo CE; Pirisi C; Sanchez O; Brosto M; Rossi R
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S1-3. PubMed ID: 2112052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ifosfamide and mesna.
    Schoenike SE; Dana WJ
    Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fatal hypokalaemia associated with ifosfamide/mesna chemotherapy.
    Husband DJ; Watkin SW
    Lancet; 1988 May; 1(8594):1116. PubMed ID: 2896952
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
    Sutton GP; Blessing JA; Rosenshein N; Photopulos G; DiSaia PJ
    Am J Obstet Gynecol; 1989 Aug; 161(2):309-12. PubMed ID: 2548382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
    Antman KH; Ryan L; Elias A; Sherman D; Grier HE
    J Clin Oncol; 1989 Jan; 7(1):126-31. PubMed ID: 2491883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Full-dose ifosfamide can be safely administered to outpatients.
    Meazza C; Bisogno G; Casanova M; Zanetti I; Carli M; Ferrari A
    Pediatr Blood Cancer; 2008 Feb; 50(2):375-8. PubMed ID: 16847930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination chemotherapy with adriamycin, ifosfamide and mesna in extensive-stage non-small cell bronchogenic carcinoma.
    Matthiessen W; Stempinski E; Göbel D; Thalmann U
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():121-3. PubMed ID: 6414688
    [No Abstract]   [Full Text] [Related]  

  • 28. [Epileptic seizures and treatment with ifosfamide-mesna].
    Somma-Mauvais H; Farisse P; Viallat JR
    Rev Neurol (Paris); 1994; 150(4):307-8. PubMed ID: 7863185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Foxall PJ; Singer JM; Hartley JM; Neild GH; Lapsley M; Nicholson JK; Souhami RL
    Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ifosfamide and Mesna in advanced malignancies.
    Li GC; Brock N; Li JQ; Guan ZZ; He YJ
    Chin Med J (Engl); 1988 Mar; 101(3):213-20. PubMed ID: 3136996
    [No Abstract]   [Full Text] [Related]  

  • 31. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.
    Pratt CB; Green AA; Horowitz ME; Meyer WH; Etcubanas E; Douglass E; Hayes FA; Thompson E; Wilimas J; Igarashi M
    J Clin Oncol; 1986 Aug; 4(8):1253-61. PubMed ID: 3090210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancer.
    Cantwell BM; Harris AL; Bozzino JM
    Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S29. PubMed ID: 3028660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
    Wiltshaw E; Westbury G; Harmer C; McKinna A; Fisher C
    Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S10-2. PubMed ID: 3102088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
    Sakurai M; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sano T; Suemasu K; Jett JR
    Jpn J Clin Oncol; 1986 Jun; 16(2):153-6. PubMed ID: 3090314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
    Ajani JA; Abbruzzese JL; Goudeau P; Faintuch JS; Yeomans AC; Boman BM; Nicaise C; Levin B
    J Clin Oncol; 1988 Nov; 6(11):1703-7. PubMed ID: 3141592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of advanced soft tissue and osteogenic sarcomas with continuous infusion of ifosfamide and mesna.
    Klein HO; Dias Wickramanayake P; Coerper C; Christian E
    Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S19. PubMed ID: 3102091
    [No Abstract]   [Full Text] [Related]  

  • 37. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
    Sanchiz F; Milla A
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S91-2. PubMed ID: 2112057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclophosphamide and ifosfamide: role of uroprotective agents.
    Williams SD; Munshi N; Einhorn LH; Loehrer PJ
    Cancer Invest; 1990; 8(2):269. PubMed ID: 2119246
    [No Abstract]   [Full Text] [Related]  

  • 39. Ifosfamide with mesna uroprotection in the management of lung cancer.
    Holoye PY; Glisson BS; Lee JS; Dhingra HM; Murphy WK; Umsawasdi T; Levy JK; Jeffries D; Raber MN; Hong WK
    Am J Clin Oncol; 1990 Apr; 13(2):148-55. PubMed ID: 2156418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
    Araujo CE; Tessler J
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):195-201. PubMed ID: 6402369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.